MDR.PA BioVector®多重耐药铜绿假单胞菌株MDR-PA Multidrug-Resistant Pseudomonas aeruginosa

BioVector® Multidrug-Resistant Pseudomonas aeruginosa (MDR-PA), a critical pathogen defined by its resistance to multiple antibiotic classes.

• 病原体名称: 多重耐药铜绿假单胞菌 (MDR-PA)

• 生物学特征: 革兰氏阴性杆菌，具有运动性（单极鞭毛），大小约为 0.5-0.8 μm x 1.5-3.0 μm。

• 耐药定义: 对至少三类抗生素（如氨基糖苷类、碳青霉烯类、头孢菌素类、氟喹诺酮类等）中的至少一种药物不敏感。

• 主要耐药机制:

  • 外排泵: 如 MexAB-OprM 系统的高表达。

  • 外膜通透性降低: 如 OprD 蛋白缺失或表达下调，导致对碳青霉烯类耐药。

  • 灭活酶: 产生 β-内酰胺酶（如 NDM-1, IMP, VIM 等碳青霉烯酶）。

  
  

• 流行病学: 在中国，MDR-PA 的检出率呈现上升趋势，特别是在 ICU 病房。常见的高风险克隆型包括 ST1971, ST244, ST357 等。

• 检测标准: 遵循 临床和实验室标准协会 (CLSI) 指南进行药敏试验。

English Version (英文版)

• Pathogen Name: Multidrug-Resistant Pseudomonas aeruginosa (MDR-PA)

• Biological Characteristics: Gram-negative, motile rod (single polar flagellum), measuring 0.5–0.8 μm by 1.5–3.0 μm.

• MDR Definition: Non-susceptibility to at least one agent in three or more antimicrobial categories (e.g., aminoglycosides, carbapenems, cephalosporins, fluoroquinolones).

• Primary Resistance Mechanisms:

  • Efflux Pumps: Overexpression of systems such as MexAB-OprM.

  • Reduced Permeability: Loss or down-regulation of OprD porins, specifically impacting carbapenem susceptibility.

  • Enzymatic Inactivation: Production of β-lactamases and carbapenemases (e.g., NDM-1, IMP-type, VIM-2).

  
  

• Epidemiology in China: Prevalence has increased over time, notably in ICUs (est. 29.0%). Predominant high-risk clones (HiRiCs) identified in mainland China include ST1971, ST244, and ST357.

• Diagnostic Standards: Susceptibility testing is typically performed using broth micro-dilution methods according to CLSI Guidelines.

Supplier生产厂家:

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947

E-mail: biovector@163.com

工作微信/QQ同号: 1843439339

http://www.biovector.net